Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113338 - METHOD OF REDUCING NEURONAL MICROTUBULE BINDING PROTEIN TAU (TAU) LEVELS

Publication Number WO/2020/113338
Publication Date 11.06.2020
International Application No. PCT/CA2019/051751
International Filing Date 05.12.2019
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 35/76 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12N 15/864 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
CPC
A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors ; , e.g. parvovirus, densovirus
Applicants
  • ADAERATA, LIMITED PARTNERSHIP [CA]/[CA]
Inventors
  • CAYOUETTE, Michel
  • LACOMME, Marine
Agents
  • LAVERY, DE BILLY, L.L.P.
Priority Data
62/775,52005.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD OF REDUCING NEURONAL MICROTUBULE BINDING PROTEIN TAU (TAU) LEVELS
(FR) PROCÉDÉ DE RÉDUCTION DES TAUX DE PROTÉINE TAU DE LIAISON AUX MICROTUBULES NEURONAUX
Abstract
(EN)
There is provided a method of reducing neuronal microtubule binding protein Tau (Tau) levels, promoting neuronal Tau degradation and/or promoting neuronal survival, in a subject in need thereof comprising contacting the subject's neurons with an effective amount of an agent that increases a long phosphotyrosine-binding (PTB) Numb isoform expression and/or activity, whereby neural Tau levels is reduced in the presence of the agent, the neuronal Tau degradation is promoted and/or the neuronal survival is promoted as compared to in the absence thereof. Also provided are methods of stratification based on PTB Numb isoform expression and/or activity of the subjects and compositions and kits for applying the methods.
(FR)
L'invention concerne un procédé de réduction des taux de protéine Tau de liaison aux microtubules neuronaux, favorisant la dégradation de la protéine Tau neuronale et/ou favorisant la survie neuronale, chez un sujet en ayant besoin, comprenant la mise en contact des neurones du sujet avec une quantité efficace d'un agent qui augmente une expression et/ou activité d'isoforme longue de Numb à liaison phosphotyrosine (PTB), ce qui permet de réduire les taux de protéine Tau neuronale en présence de l'agent, de favoriser la dégradation de la protéine Tau neuronale et/ou la survie neuronale comparé à l'absence de celle-ci. L'invention concerne également des procédés de stratification basés sur l'expression et/ou l'activité d'isoforme de Numb PTB des sujets, et des compositions et des kits pour appliquer les procédés.
Latest bibliographic data on file with the International Bureau